Bioprospect is so small and under the radar it is not surprising, most investors will not have heard of it. Theews is detailed and many will not study or analyze its implications. If it gets some coverage with this news in national news print who knows where it will go. Being in with Solagran will bring the financial editors to the table and if they see what I saw in the news.......any one's guess.